Triple Hair

Triple Hair is a Canadian clinical-stage biotechnology company dedicated to developing and commercializing innovative solutions for hair regrowth. The company's flagship product, TH07, is a patented topical prescription therapy that combines minoxidil, finasteride, and latanoprost, currently undergoing Phase 3 clinical trials for the treatment of androgenetic alopecia. In addition to its clinical pipeline, Triple Hair operates a commercial division with over-the-counter brands like RIZN and Plenty, targeting the premium hair care market. The company aims to provide more effective alternatives to existing hair loss treatments through synergistic multi-drug formulations that target multiple pathways of hair follicle biology.